About: Laboratory Testing Implications of Risk-Stratification and Management for Improving Clinical Outcomes of COVID-19 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Laboratory Testing Implications of Risk-Stratification and Management for Improving Clinical Outcomes of COVID-19 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Laboratory Testing Implications of Risk-Stratification and Management for Improving Clinical Outcomes of COVID-19 Patients
Creator	Li, Jie Wu, Wei Wang, Jie Liu, Ziyu Xiang, Drs, † Gao, Yingdong Hou, Weiye Li, Changgang Liu, Caidong Nie, Zhenling Sun, Huiling Wang, Qianghu Wang, Shukui Wang, Youli Wang, Ziyu Wu, Lingxiang Xia, Xinyi Xiang, Changgang Zhang, Ruisheng
Source	MedRxiv
abstract	The high mortality rate of COVID-19 patients is mainly caused by the progression from mild to critical illness. To identify the key laboratory indicators and stratify high-risk COVID-19 patients with progression to severe/critical illness, we compared 474 moderate patients and 74 severe/critical patients. The laboratory indicators, including lactate dehydrogenase (LDH), monocytes percentage, etc. were significantly higher in the severe/critical patients (P <0.001) and showed a noticeable change at about a week before the diagnosis. Based on these indicators, we constructed a risk-stratification model, which can accurately grade the severity of patients with COVID-19 (accuracy = 0.96, 95% CI: 0.94 - 0.989, sensitivity = 0.98, specificity = 0.84). Also, compared with non-COVID-19 viral pneumonia, we found that COVID-19 had weaker dysfunction to the heart, liver, and kidney. The prognostic model based on laboratory indicators could help to diagnose, monitor, and predict severity at an early stage to those patients with COVID-19.
has issue date	2020-06-14(xsd:dateTime)
bibo:doi	10.1101/2020.06.12.20129098
has license	medrxiv
sha1sum (hex)	b3b394f18ba95c095083243dc921182b2209824b
schema:url	https://doi.org/10.1101/2020.06.12.20129098
resource representing a document's title	Laboratory Testing Implications of Risk-Stratification and Management for Improving Clinical Outcomes of COVID-19 Patients
resource representing a document's body	covid:b3b394f18ba95c095083243dc921182b2209824b#body_text
is schema:about of	named entity 'model' named entity 'patients' named entity 'randomly' named entity 'indicators' named entity 'change' named entity 'ABOUT' named entity 'MORTALITY RATE' named entity 'THESE' covid:arg/b3b394f18ba95c095083243dc921182b2209824b named entity 'indicators' named entity 'indicators' named entity 'measurements' named entity 'blood' named entity 'patients' named entity 'feature' named entity 'kidney' named entity 'constructed' named entity 'monitor' named entity 'monocytes' named entity 'liver' named entity 'COVID' named entity 'COVID' named entity 'monocytes' named entity 'COVID' named entity 'critical illness' named entity 'high-risk' named entity 'ensemble learning' named entity 'Clinical Outcomes' named entity 'prognostic' named entity 'Missing values' named entity 'patients' named entity 'comorbidity' named entity 'hemoglobin' named entity 'cross-validation' named entity 'ROC' named entity 'NT-proBNP' named entity 'procalcitonin' named entity 'Huoshenshan hospital' named entity 'ACE2' named entity 'heart disease' named entity 'diabetes' named entity '2, 3' named entity 'ACE2' named entity 'principal component analysis' named entity 'Kang Zhang' named entity 'liver dysfunction' named entity 'Fisher's exact test' named entity 'liver' named entity 'critical illness' named entity 'SARS-CoV-2' named entity 'Hypertension' named entity 'heart disease' named entity 'comorbidities' named entity 'cross-validation' named entity 'cTnT' named entity 'clinical diagnosis' named entity 'activated partial thromboplastin time' named entity 'protein' named entity 'NT-proBNP' named entity 'COVID' named entity 'hypertension' named entity 'COVID-19' named entity 'epidemics' named entity 'moderate cases' named entity 'vital information' named entity 'prognosis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software